How Do Adrenergic Antagonists Block Receptors?

TL;DR

Adrenergic antagonists inhibit sympathetic activity by blocking alpha or beta adrenergic receptors, changing vascular tone, cardiac output, bronchodilation, contraction, conduction, or secretion according to receptor subtype and tissue. Selective, nonselective, and mixed agents are used for conditions including hypertension, angina, heart failure, arrhythmias, pheochromocytoma, glaucoma, and benign prostatic hyperplasia, but can cause bradycardia, bronchospasm, orthostatic hypotension, fatigue, or rebound hypertension.

Transcript

what's up ninja nerds in this video today we are going to be talking about the adrenergic antagonists so this is going to be really a discussion on alpha blockers and beta blockers if you really want to think about that but what we have to do before we actually start talking about alpha blockers and beta blockers is we really need to go through our... Read More

Key Insights

• Norepinephrine synthesis begins with tyrosine uptake into an adrenergic nerve terminal through a sodium cotransporter. Tyrosine becomes L-DOPA and then dopamine, which enters a vesicle and is enzymatically converted into norepinephrine before being stored for release.
• Norepinephrine release is triggered when an action potential opens voltage-gated calcium channels. The resulting calcium influx strongly stimulates norepinephrine-containing vesicles to fuse with the cell membrane, releasing their contents into the synaptic cleft through exocytosis.
• Alpha-1 receptors signal through a Gq protein that increases IP3, DAG, and intracellular calcium. In smooth muscle cells, the increased calcium promotes contraction, so antagonizing these receptors can interfere with sympathetic effects involving smooth muscle tone.
• Alpha-2 receptors signal through an inhibitory G protein that reduces cyclic AMP and increases potassium efflux. These changes can hyperpolarize neurons or other cells and inhibit the release or secretion of particular substances.
• Beta receptors signal through stimulatory G proteins that increase cyclic AMP, but their effects depend on the tissue. Beta-1 signaling can stimulate contraction, conduction, and secretion, while beta-2 and beta-3 signaling can inhibit contraction and promote relaxation.
• Norepinephrine activity ends through metabolism or recycling. Catechol methyl transferase can convert extracellular norepinephrine into an inactive metabolite, while a norepinephrine reuptake transporter returns it to the nerve terminal for vesicular reuse or further metabolism.
• Monoamine oxidase is located within mitochondria and provides another pathway for norepinephrine inactivation after reuptake. Recycled norepinephrine can either return to a storage vesicle for later use or be converted into an inactive metabolite by this enzyme.
• Adrenergic antagonists are categorized as alpha blockers, beta blockers, or mixed alpha and beta blockers. The listed agents affect sympathetic functions and are discussed in relation to receptor selectivity, vascular tone, cardiac output, bronchodilation, clinical indications, and adverse effects.

Questions & Answers

Q: How is norepinephrine synthesized in adrenergic neurons?

Norepinephrine synthesis starts when tyrosine enters an adrenergic nerve terminal through a sodium cotransporter. Inside the neuron, tyrosine is converted into L-DOPA, and L-DOPA is then converted into dopamine. Dopamine is transported into a synaptic vesicle, where specific enzymes metabolize it into norepinephrine. The resulting norepinephrine remains stored in the vesicle until neuronal stimulation initiates its release.

Q: How is norepinephrine released into the synaptic cleft?

An action potential traveling down the adrenergic neuron activates voltage-gated calcium channels at the nerve terminal. Calcium then rushes into the cell and acts as a strong stimulus for synaptic vesicle fusion. Vesicles containing norepinephrine merge with the cell membrane and release the transmitter into the synaptic cleft by exocytosis, allowing it to bind adrenergic receptors on target cells.

Q: How does alpha-1 receptor signaling affect smooth muscle?

Alpha-1 receptor stimulation activates a Gq protein, which increases the signaling molecules IP3 and DAG. The overall effect is an increase in intracellular calcium. In smooth muscle cells, higher calcium levels promote contraction. Alpha-1 antagonists therefore block a receptor pathway associated with smooth muscle contraction, which is relevant to their effects on sympathetic function and vascular tone.

Q: How do alpha-2 receptors inhibit cellular activity?

Alpha-2 receptors work through an inhibitory G protein that lowers cyclic AMP levels. Their activation also increases potassium efflux, which can contribute to hyperpolarization of neurons or other cells. These signaling changes inhibit processes that would otherwise support the release or secretion of particular substances. Alpha-2 signaling therefore has an inhibitory role within the adrenergic system described in the lecture.

Q: Why can beta receptors produce different tissue responses?

Beta-1, beta-2, and beta-3 receptors all activate stimulatory G proteins and increase cyclic AMP, but the resulting physiological response depends on the cell or tissue involved. Beta-1 signaling can stimulate contraction, conduction, and secretion. Beta-2 and beta-3 signaling can instead inhibit contraction and cause relaxation because cyclic AMP activates processes that phosphorylate and inactivate enzymes involved in contraction or secretion.

Q: How is norepinephrine removed or recycled after signaling?

Norepinephrine can follow several pathways after exerting its effect. Catechol methyl transferase can break it down into an inactive metabolite outside the neuron. Alternatively, a norepinephrine reuptake transporter can carry it back into the nerve terminal. Reabsorbed norepinephrine may be returned to a synaptic vesicle for later reuse or metabolized into an inactive product by mitochondrial monoamine oxidase.

Q: Which drugs are categorized as adrenergic antagonists?

The listed alpha blockers are prazosin, doxazosin, phenoxybenzamine, and phentolamine. The listed beta blockers are propranolol, metoprolol, atenolol, labetalol, carvedilol, esmolol, and timolol. Labetalol and carvedilol are also identified as mixed alpha and beta blockers. These agents are organized further according to whether their receptor effects are selective or nonselective.

Q: What are the uses and adverse effects of adrenergic antagonists?

Adrenergic antagonists are described as treatments for hypertension, angina, heart failure, arrhythmias, pheochromocytoma, glaucoma, and benign prostatic hyperplasia. Their receptor blockade can affect vascular tone, cardiac output, and bronchodilation. The adverse effects listed in the source include bradycardia, bronchospasm, orthostatic hypotension, fatigue, and rebound hypertension, with the relevant risks depending on the antagonist and its receptor selectivity.

Summary & Key Takeaways

• Norepinephrine synthesis begins when a sodium cotransporter carries tyrosine into an adrenergic nerve terminal. Tyrosine is converted first into L-DOPA and then dopamine. Dopamine enters a vesicle, where enzymes convert it into norepinephrine, preparing the transmitter for storage and eventual release into the synaptic cleft after neuronal stimulation.

• An action potential activates voltage-gated calcium channels, causing calcium to enter the nerve terminal and stimulate vesicle fusion. Exocytosis releases norepinephrine, which can bind alpha-1, alpha-2, beta-1, beta-2, or beta-3 receptors. Each subtype uses a particular signaling pathway that affects contraction, relaxation, conduction, or secretion in target tissues.

• Adrenergic antagonists include selective and nonselective alpha blockers, beta blockers, and mixed alpha and beta blockers. Their receptor blockade affects vascular tone, cardiac output, and bronchodilation. The described clinical applications include hypertension, angina, heart failure, arrhythmias, pheochromocytoma, glaucoma, and benign prostatic hyperplasia, with adverse effects varying by receptor activity.